Changes in the Board of Directors
January 16 2018 - 6:22AM
Changes in the Board of Directors
Today it is announced that BioPorto’s Board of
Directors will nominate Britt Meelby Jensen for election as a new
Board member at BioPorto’s Annual General Meeting on April 13,
2018.
Britt Meelby Jensen (Danish citizen, born 1973)
has extensive global commercial and general management experiences
from working in the life sciences area over the past 16 years at
Novo Nordisk, Dako and Zealand Pharma. Since 2015 Britt has been
the CEO of Zealand Pharma A/S, a medium sized biotech company
listed on NASDAQ in Copenhagen and New York. Britt Meelby Jensen
holds a Master of Science from Copenhagen Business School and a
Master in Business Administration from Solvay Business School in
Brussels, Belgium.
Thomas Magnussen, Chairman of the Board, says:
“We are delighted with the opportunity to nominate Britt for
election to the Board at the upcoming general meeting. She brings
unique international management skills and commercial insights that
are complementary to the existing team. We look forward to
welcoming Britt on the Board.”
For further information, please
contact:
Thomas Magnussen, Chairman of the Board of
Directors Telephone +45 4529 0000, e-mail investor@bioporto.com
About BioPorto
BioPorto Diagnostics A/S is an in-vitro
diagnostics company that provides healthcare professionals in
clinical and research settings a range of diagnostic tests and
antibodies. Our pioneering product portfolio includes assays for
underserved disease states such as NGAL for acute kidney injury.
BioPorto has its headquarters in Copenhagen, Denmark and is listed
on the Nasdaq Copenhagen stock exchange.
http://prlibrary-eu.nasdaq.com/Resource/Download/dd42c247-7537-481d-84b8-6c4ed488a0e9
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioporto A/s (LSE:0JJM)
Historical Stock Chart
From Apr 2023 to Apr 2024